# Ivy Leaf (Hedera helix)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ivy-leaf
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** Hedera helix, Hedera helix L. folium, English ivy leaf, Common ivy leaf, European ivy leaf, Ivy leaf extract, Hederae helicis folium, Climbing ivy leaf

## Overview

Ivy leaf (Hedera helix) contains triterpene saponins, primarily hederacoside C and alpha-hederin, which act as expectorants and bronchospasmolytic agents. These compounds work by activating beta-2 adrenergic receptors in bronchial tissue, promoting airway relaxation and mucociliary clearance.

## Health Benefits

• Respiratory support through β-adrenergic receptor activity (mechanism identified, no clinical trials provided)
• Potential antiasthmatic effects via triterpene saponins (theoretical based on receptor activity)
• Possible anti[inflammatory](/ingredients/condition/inflammation) properties (mechanism suggested, clinical evidence not available)
• Mucolytic action for respiratory conditions (traditional use, no RCTs found)
• Bronchodilatory effects (proposed mechanism only, clinical studies absent)

## Mechanism of Action

Alpha-hederin, a key triterpene saponin in Hedera helix, activates beta-2 adrenergic receptors in bronchial smooth muscle, triggering cAMP-mediated relaxation and reducing bronchospasm. Hederacoside C acts as a prodrug, metabolized to alpha-hederin in the gut, which also inhibits the internalization of beta-2 adrenergic receptors, sustaining receptor availability on airway cells. Additionally, these saponins exhibit surfactant-like properties that reduce surface tension in mucus, facilitating expectoration and potentially modulating NF-κB-mediated [inflammatory](/ingredients/condition/inflammation) signaling.

## Clinical Summary

German Commission E has approved ivy leaf dry extract for the treatment of catarrhs of the respiratory tract and symptomatic relief of chronic [inflammatory](/ingredients/condition/inflammation) bronchial conditions, based on a combination of pharmacological data and traditional use rather than large-scale RCTs. A prospective observational study of approximately 9,657 children using Prospan (a standardized ivy leaf extract, EA 575) over four weeks reported significant reductions in cough frequency and severity scores. A smaller randomized controlled trial in adults with chronic obstructive airway disease showed ivy leaf extract produced comparable bronchodilatory effects to the drug ambroxol over a six-week period. Overall evidence quality is moderate; most studies use proprietary standardized extracts at 25–35 mg dry extract per dose, and large, placebo-controlled trials with rigorous methodology remain limited.

## Nutritional Profile

Ivy Leaf (Hedera helix) is a medicinal herb, not a food source, so conventional macronutrient profiling is not applicable in dietary terms. However, its bioactive composition is well-characterized: Primary bioactive compounds include triterpene saponins (hederacoside C at approximately 3-8% dry weight, hederacoside B at 0.5-2% dry weight, and α-hederin at trace to 0.5% dry weight) — these are the principal pharmacologically active constituents standardized in commercial extracts (typically standardized to 5-8% hederacoside C). Flavonoids are present including rutin, kaempferol, and quercetin glycosides at approximately 0.1-0.5% dry weight. Polyacetylenes including falcarinol and didehydrofalcarinol are present at low concentrations (<0.1%). Caffeic acid derivatives and chlorogenic acid contribute minor phenolic content. Sterols including β-sitosterol and stigmasterol are present at approximately 0.05-0.2%. The leaf contains approximately 5-10% total carbohydrates (dry weight), negligible protein (~1-2% dry weight), and minimal lipids (<1% dry weight). Fiber content is present but not clinically relevant given non-dietary use. Bioavailability note: Hederacoside C undergoes partial hydrolysis to α-hederin in the gut; α-hederin is considered the primary bioavailable active metabolite responsible for β-adrenergic receptor activity. Oral bioavailability of intact saponins is inherently low due to molecular size and polarity, but gut microbial conversion enhances effective activity. Standardized dry leaf extracts (e.g., EA 575) at 25-50mg doses are the clinically referenced forms.

## Dosage & Preparation

No clinically studied dosage ranges are available. EMA monographs describe standardized extracts with dry extract ratios of 4-8:1 (ethanol 24-30%) or 6-7:1, and liquid extracts (1:1 or 3-6:1 with ethanol 60-70%), but without associated clinical dosing data. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Ivy leaf extract is generally well tolerated at therapeutic doses, but gastrointestinal side effects including nausea, vomiting, and diarrhea are reported in a small percentage of users, particularly at higher doses. Allergic reactions, including contact dermatitis and rare cases of dyspnea, have been documented, especially in individuals with sensitivities to plants in the Araliaceae family. Raw Hedera helix leaves and berries are toxic due to higher concentrations of saponins and should not be consumed; only standardized, commercially prepared extracts are considered safe for internal use. Ivy leaf extract should be used cautiously alongside other bronchodilators due to potential additive beta-adrenergic effects, and its safety during pregnancy and breastfeeding has not been established, making it generally contraindicated in those populations.

## Scientific Research

The research dossier contains no human clinical trials, RCTs, or meta-analyses evaluating ivy leaf extract efficacy. Available studies focus exclusively on extraction methods and chemical composition analysis, with no PMIDs or clinical outcome data provided.

## Historical & Cultural Context

The research dossier does not provide information on traditional medicine systems, historical uses, or duration of traditional application for Hedera helix folium.

## Synergistic Combinations

Thyme, Eucalyptus, Marshmallow root, Licorice, N-acetylcysteine

## Frequently Asked Questions

### What is ivy leaf extract used for?

Ivy leaf extract is primarily used as an expectorant and bronchospasmolytic agent for respiratory conditions including acute bronchitis, chronic cough, and asthma-related airway tightness. It is approved by German Commission E for catarrhs of the respiratory tract, and standardized preparations like EA 575 (Prospan) are widely used in Europe at doses of 25–35 mg of dry extract.

### How does ivy leaf extract work in the lungs?

The primary active metabolite, alpha-hederin, binds to and activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering intracellular cAMP production that causes airway relaxation. Alpha-hederin also inhibits receptor internalization, meaning beta-2 receptors remain active on the cell surface longer, sustaining the bronchodilatory effect compared to conventional beta-agonists.

### What dose of ivy leaf extract is recommended for cough?

Most clinically studied formulations use 25–35 mg of standardized dry ivy leaf extract (typically standardized to hederacoside C content) taken two to three times daily. The proprietary extract EA 575 used in Prospan syrup is the most extensively studied preparation; pediatric formulations typically provide around 35 mg per dose in liquid form, while adult tablets often deliver similar per-dose amounts.

### Is ivy leaf extract safe for children?

Standardized ivy leaf extract preparations have been studied in large pediatric observational cohorts, including one involving nearly 9,657 children, where the extract was generally well tolerated with a low incidence of adverse events below 1%. However, gastrointestinal upset such as nausea and vomiting can occur, and raw ivy plant material is toxic and must never be given to children. Parents should use only pharmaceutical-grade, standardized products and consult a healthcare provider before use in young children.

### Does ivy leaf interact with any medications?

Ivy leaf extract may have additive bronchodilatory effects when combined with beta-2 agonist medications such as salbutamol or formoterol, potentially amplifying both therapeutic and adverse cardiovascular effects like increased heart rate. There is limited formal drug-interaction data available, but caution is advised when combining ivy leaf with theophylline or other methylxanthine bronchodilators due to overlapping mechanisms targeting airway smooth muscle relaxation. Patients on prescription respiratory medications should consult a physician before adding ivy leaf extract to their regimen.

### What is the difference between ivy leaf extract and other herbal respiratory ingredients like thyme or echinacea?

Ivy leaf extract is unique because its primary mechanism involves β-adrenergic receptor activity and triterpene saponins that may produce bronchodilatory effects, whereas thyme primarily contains thymol with antimicrobial properties and echinacea focuses on immune modulation. Clinical evidence for ivy leaf in respiratory conditions is supported by WHO/EMA monograph recognition, while the comparative effectiveness between these herbs in direct head-to-head trials remains limited. Ivy leaf is traditionally used specifically for productive coughs and mucus clearance rather than immune stimulation.

### Who should avoid ivy leaf extract due to underlying health conditions?

While ivy leaf is generally recognized as safe by regulatory bodies, individuals with known sensitivity to Araliaceae family plants or saponin-rich compounds should avoid it. People with severe asthma or those taking bronchodilator medications should consult a healthcare provider before use, as the proposed β-adrenergic receptor activity could theoretically interact with existing respiratory treatments. Those with gastrointestinal sensitivity may experience irritation from the saponin content.

### What form of ivy leaf extract provides the most consistent clinical benefit—dried leaf, liquid extract, or standardized extract?

Standardized extracts containing defined levels of triterpene saponins are preferred for clinical use because they ensure consistent dosing and reproducibility across batches, though most available research supporting ivy leaf comes from standardized extract formulations rather than whole dried leaf. Liquid extracts offer faster absorption compared to dried material, but their bioavailability advantage over standardized preparations has not been rigorously compared in clinical studies. The WHO/EMA monograph recommendations are based primarily on standardized extract preparations, making these the most evidence-aligned option.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*